Delta posts nearly $1.2 billion quarterly loss, expects to break even in June as bookings improve
Delta says bookings have improved over the past several months and expects to break even by June. (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2021 Category: Consumer Health News Source Type: news

Delta posts wider-than-expected Q1 loss but CEO Bastian sees 'pathway to profitability' by June
Delta Air Lines lost $2.9 billion in the first quarter but CEO Ed Bastian sees a pathway to profitability by June. (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2021 Category: Consumer Health News Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

IMF, World Bank Must Support Developing Countries ’ Recovery
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Apr 6 2021 (IPS) The COVID-19 pandemic continues to take an unprecedented human and economic toll, wiping away years of modest and uneven progress towards the Sustainable Development Goals (SDGs). Developing countries now need much more support as progress towards the SDGs was ‘not on track’ even before the pandemic. Anis ChowdhuryBy end-2022, average incomes are expected to be 18% below pre-crisis levels in low-income countries (LICs) and 22% less in emerging and developing countries excluding China – compared to 13% lower for developed e...
Source: IPS Inter Press Service - Health - April 6, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Development & Aid Economy & Trade Financial Crisis Global Headlines Health Humanitarian Emergencies Poverty & SDGs TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

As New CEO Takes Helm, Walgreens Profits Rise Amid Vaccine Rollout
Walgreens Boots Alliance reported $1 billion in quarterly profits, beating Wall Street ’s earnings expectations during a major rollout of vaccines against Covid-19 at its drugstores. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 31, 2021 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Retail /retail pharma Source Type: news

IMF, World Bank Must Urgently Help Finance Developing Countries
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Mar 30 2021 (IPS) COVID-19 has set back the uneven progress of recent decades, directly causing more than two million deaths. The slowdown, due to the pandemic and policy responses, has pushed hundreds of millions more into poverty, hunger and worse, also deepening many inequalities. Anis ChowdhuryDevelopment setbacks The outlook for developing countries is grim, with output losses of 5.7% in 2020. Compared to pre-pandemic trends, the expected 8.1% loss by end-2021 will be much worse than advanced countries dropping 4.7%. COVID-19 has further set back progr...
Source: IPS Inter Press Service - Health - March 30, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Development & Aid Economy & Trade Financial Crisis Global Headlines Health Humanitarian Emergencies Inequity Poverty & SDGs TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, NJ (March 29, 2021) - Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union’s 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful appr...
Source: Johnson and Johnson - March 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Credit Suisse takes hit from U.S. hedge fund; warns of 'highly significant' losses
Credit Suisse warned of a hit to its first-quarter results after it began exiting positions with a large U.S. hedge fund. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2021 Category: Consumer Health News Source Type: news

Janssen Receives Positive CHMP Opinion for PONVORY ™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features
BEERSE, BELGIUM, MARCH 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[3]“Relapsing forms of multiple sclerosis (MS) have varied and often unpredictable symptoms, posing a unique human, societal and economic burden,” said Catherine T...
Source: Johnson and Johnson - March 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CARES Act funds boost Advocate Aurora's 2020 financial results, patient activity rebounds
Advocate Aurora Health ’s financial results rebounded somewhat in the fourth quarter of 2020, but that didn’t make up for losses sustained earlier in the year due to the Covid-19 pandemic. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 25, 2021 Category: American Health Authors: Rich Kirchen Source Type: news

Johnson & Johnson Announces Five Initiatives to Help Find the ‘Missing Millions’ of Undiagnosed People Living with Tuberculosis
NEW BRUNSWICK, N.J., 24 March 2021 – In recognition of World Tuberculosis (TB) Day, Johnson & Johnson today announced a series of new commitments and collaborations in support of global efforts to find and deliver care to the millions of adults and children living with TB who have not yet been diagnosed. Successfully identifying these people, especially those living with multidrug-resistant TB (MDR-TB), remains one of the most significant obstacles in achieving the United Nations (UN) Sustainable Development Goal of ending TB by 2030. These initiatives—together with the Global Fund to Fight AIDS, Tuberculos...
Source: Johnson and Johnson - March 24, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Nike lays off more workers but says shoe market remains strong
The sneaker giant quietly implemented more job reductions in recent weeks, it confirmed. The company posted big quarterly profits... (Source: Reuters: Health)
Source: Reuters: Health - March 19, 2021 Category: Consumer Health News Source Type: news

How Industrial Fishing Creates More CO2 Emissions Than Air Travel
It’s been well established by now that the agricultural systems producing our food contribute at least one fifth of global anthropogenic carbon emissions—and up to a third if waste and transportation are factored in. A troubling new report points to a previously overlooked source: an industrial fishing process practiced by dozens of countries around the world, including the United States, China, and the E.U. The study, published today in the scientific journal Nature, is the first to calculate the carbon cost of bottom trawling, in which fishing fleets drag immense weighted nets along the ocean floor, scraping ...
Source: TIME: Science - March 17, 2021 Category: Science Authors: Aryn Baker Tags: Uncategorized embargoed study Explainer Londontime overnight TIME 2030 Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Juwan Howard ejected, exchanges words with Mark Turgeon in Maryland ’s loss to Michigan in Big Ten quarterfinals
Wolverines coach Juwan Howard received two technical fouls and was ejected during an under-12 media timeout after exchanging words with... (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
NEW BRUNSWICK, N.J., March 12, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants give...
Source: Johnson and Johnson - March 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Victoria's Secret owner L Brands shares rise after retailer hikes outlook, reinstates dividend
L Brands on Friday hiked its profit outlook for the current quarter, and said it would be reinstating an annual dividend and paying down debt. (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).2 The CMA is valid in all 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstei...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recommend the Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percen...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Bone Loss Common in Kidney Stone Patients, yet Rarely Detected Bone Loss Common in Kidney Stone Patients, yet Rarely Detected
Almost one quarter of patients diagnosed with kidney stones have osteoporosis or a fracture history on diagnosis, yet few undergo bone mineral density screening, especially men.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both month...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

How immigration policies can harm health: Study sheds light on ‘public charge’ rule
Immigration policies like the Trump-era expansion of the “public charge” rule that made it harder for immigrants on public assistance to obtain legal residency can have a chilling effect on the health and well-being of immigrant communities in California, according to astudy released today by theUCLA Center for Health Policy Research.The study, based on data from  the center ’s 2019 California Health Interview Survey, shows  that 1 in 4 low-income immigrant adults in the state  have  avoided accessing public assistance like health, food or housing programs at some point for fear o...
Source: UCLA Newsroom: Health Sciences - March 2, 2021 Category: Universities & Medical Training Source Type: news

Cumberland Infirmary workers stage second strike
UNISON members at Cumberland Infirmary are taking a second day of strike action today as their private employer refuses to end a decade of missing payments. More than 150 porters, cleaners, switchboard and catering staff employed at Cumberland Infirmary by facilities company Mitie, took a first day of action on Friday over missing payments for working unsocial hours. Workers directly employed by the NHS receive enhanced rates – such as time-and-a-half and double time – for working at unsocial times such as weekends or through the night. But UNISON has discovered that the Cumberland Infirmary staff have not rece...
Source: UNISON Health care news - March 1, 2021 Category: UK Health Authors: Amanda Kendal Tags: Article News Cumberland Infirmary Mitie North West Source Type: news

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agai...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Lantheus experiences net loss in Q4, full fiscal year
A slight increase in revenue for the fourth quarter wasn't enough to offse...Read more on AuntMinnie.comRelated Reading: Lantheus touts ASCO GU talks with PSMA agent Lantheus submits drug master file for imaging biomarker Point Biopharma to use Lantheus' PyL in clinical trial Lantheus divests Puerto Rico nuclear medicine businesses FDA clears Lantheus' AI bone software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 27, 2021 Category: Radiology Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are e...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Humana execs sell nearly $28M in company shares
The Louisville-based health care giant is coming off a year in 2020 that saw a rare quarterly loss in the fourth quarter, but increases in revenue and income for the year in total. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 24, 2021 Category: Health Management Authors: Chris Larson Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a sta...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Macy's holiday sales top estimates, lifting company to its first profitable quarter in a year
Macy's reported its first quarterly profit in a year, as its efforts to slash inventories during the holiday quarter and rely less on... (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2021 Category: Consumer Health News Source Type: news

Coronavirus symptoms: 22% of patients have long-term hair loss
Almost a quarter of Covid-19 survivors may be dealing with hair loss, according to a new paper by experts from the Chinese Academy of Medical Sciences. (Source: the Mail online | Health)
Source: the Mail online | Health - February 22, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 19, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered today includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our u...
Source: Johnson and Johnson - February 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Overcoming the Learning Divide: Assessing What Students Missed During School Closings for COVID-19
Remote teaching in Bangladesh. Credit: BRACBy Safiqul IslamDHAKA, Bangladesh, Feb 19 2021 (IPS) School closings and the varied impacts of remote learning amid the COVID-19 pandemic are a global challenge. Educators worldwide have been struggling to meet contemporary educational standards in this environment. But this challenge is followed by yet another: how to assess the readiness of students to resume in-school education when schools open. At BRAC, the international nongovernmental organization that operates 25,000 schools in Bangladesh, serving 750,000 students, we have developed an approach that could be helpful. Scho...
Source: IPS Inter Press Service - Health - February 19, 2021 Category: International Medicine & Public Health Authors: Safiqul Islam Tags: Aid Asia-Pacific Education Headlines Health Humanitarian Emergencies TerraViva United Nations Source Type: news

Unions hold last-ditch talks to avert Cumberland Infirmary strike
UNISON and GMB are holding crunch talks with Mitie and North Cumbria Integrated Care NHS Foundation Trust, in a last-ditch attempt to avoid strike action. More than 150 porters, cleaners, switchboard and catering staff employed by Mitie at Cumberland Infirmary are set to stage 24-hour strikes on Friday 26 February and again on Monday 1 March over missing payments for working unsocial hours. NHS workers receive enhanced rates – such as time-and-a-half and double time – for working at unsocial times such as weekends or through the night. But UNISON has discovered that the Cumberland Infirmary staff have not recei...
Source: UNISON meat hygiene - February 18, 2021 Category: Food Science Authors: Amanda Kendal Tags: Article Cumberland Infirmary Industrial action North West outsourcing strike Source Type: news

Credit Suisse swings to fourth-quarter loss, weighed down by provisions for a U.S. legal dispute
Credit Suisse reported Thursday a net loss of 353 million Swiss francs ($392.8 million) for the fourth quarter of 2020 on the back of... (Source: Reuters: Health)
Source: Reuters: Health - February 18, 2021 Category: Consumer Health News Source Type: news

IP, Vaccine Imperialism Cause Death and Suffering, Delay Recovery
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Feb 16 2021 (IPS) Vaccine developers’ refusal to share publicly funded vaccine research findings is stalling broader, affordable vaccinations which would more rapidly contain COVID-19 contagion. The pandemic had infected at least 109 million people worldwide, causing over 2.4 million deaths as of mid-February. Anis Chowdhury Avoidable delays in preventive vaccination are imposing terrible burdens on the world economy and human welfare, with economic disruption demanding more relief and recovery measures. They have cost US$28 trillion in lost output gl...
Source: IPS Inter Press Service - Health - February 16, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Aid Development & Aid Economy & Trade Featured Financial Crisis Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

New phase III data show Roche ’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients
Basel, 12 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up to four months, offered non-inferior vision gains compared to aflibercept, given every two months. Approximately half of people eligible for extended dosing with faricimab were able to be treated every four months in the first year in the YOSEMITE and ...
Source: Roche Investor Update - February 12, 2021 Category: Pharmaceuticals Source Type: news

New phase III data show Roche ’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients
Basel, 12 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or “wet” age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up to four months, offered non-inferior vision gains compared to aflibercept, given every two months. Approximately half of people eligible for extended dosing with faricimab were able to be treated every four months in the first year in the YOSEMITE and ...
Source: Roche Media News - February 12, 2021 Category: Pharmaceuticals Source Type: news

Molina Latest Health Insurer Hit By Rising Covid-19 Costs
Molina Healthcare ’s profits dipped in the fourth quarter and for the full year of 2020 as the Covid-19 pandemic triggered rising expenses and an uptick in medical claims for the health insurer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 10, 2021 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Editors' Pick editors-pick Coronavirus Decision Maker Content decisionmaker pharma Source Type: news

GM earnings top estimates
General Motors Co.'s fourth-quarter profit cruised past Wall Street's expectations, capping a striking rebound in the second half of... (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2021 Category: Consumer Health News Source Type: news

Container shipping locked in a 'significant bottleneck' as demand surges back
Maersk, the world's largest container shipping firm, marginally beat fourth-quarter profit expectations Wednesday after an "exceptional... (Source: Reuters: Health)
Source: Reuters: Health - February 10, 2021 Category: Consumer Health News Source Type: news

Lyft stock rises more than 10% after company reports signs of pandemic recovery
Lyft reported fourth-quarter losses of $458.2 million for the fourth quarter of 2020. (Source: Reuters: Health)
Source: Reuters: Health - February 9, 2021 Category: Consumer Health News Source Type: news

With $110B In Revenue, Centene Looks To Diversify With Magellan ’s Mental Health Business
Health insurer Centene reported a fourth quarter loss due to costs of the Covid-19 pandemic and acquisition expenses as the company adds more services that will continue into 2021 with the addition of Magellan Health. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 9, 2021 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick business pharma Source Type: news

Chiefs' Patrick Mahomes ran for nearly 500 yards in Super Bowl LV loss to Buccaneers
Kansas City Chiefs quarterback Patrick Mahomes had five carries for 33 yards in the team’s 31-9 loss to the Tampa Bay Buccaneers in... (Source: Reuters: Health)
Source: Reuters: Health - February 9, 2021 Category: Consumer Health News Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Varex's Q1 revenues down from last year
Varex Imaging announced its financial results for the first quarter of fisca...Read more on AuntMinnie.comRelated Reading: Varex to showcase new x-ray tech, software at RSNA Varex sees drop in revenues, swings to net loss in Q4 Varex announces $300M private offering Varex adds healthcare veteran Timothy Guertin to board Varex debuts new x-ray components at ECR 2020 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2021 Category: Radiology Source Type: news

Domestic Violence Is a Pandemic Within the COVID-19 Pandemic
The last thing Sheila wanted to do on May 21 was drive her car. Getting behind the wheel with a concussion, multiple skull hematomas, and bruises and abrasions across her body was a decidedly bad idea. But it was the only way her husband would have let her out of the house. She told him she was going out to buy him cigarettes. The truth was, Sheila (a pseudonym to protect her identity) was heading to meet her pastor’s wife, who worked at one of the offices in the city hall of her small Nebraska town, seeking help to escape the domestic hell in which she’d been living since the start of spring. That was when the...
Source: TIME: Health - February 3, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news

Humana Hit Hard By Covid-19 Costs As Medicare Advantage Enrollment Rises
Humana reported a $458 million fourth quarter loss as the health insurer was hit by costs related to the Covid-19 pandemic and the expense of testing and treating these patients in the last two months of 2020. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 3, 2021 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Editors' Pick editors-pick Coronavirus Decision Maker Content decisionmaker pharma Source Type: news